V S International Private Limited

V S International Private Limited, incorporated on July 25, 1997, is a privately held Indian pharmaceutical exporter headquartered in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U85100MH1997PTC109647. As of the latest available data, V S International has an authorized share capital of ₹12,500,000 and a paid-up capital of ₹11,664,700. The company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

V S International Private Limited operates manufacturing facilities in India, strategically located to serve both domestic and international markets. While specific details regarding plant locations and capacities are not publicly disclosed, the company's export portfolio indicates a focus on high-demand pharmaceutical products. The manufacturing plants are equipped to produce a range of dosage forms, including tablets, capsules, syrups, and injections, catering to diverse therapeutic needs.

The leadership team at V S International Private Limited comprises individuals with extensive experience in the pharmaceutical industry. The company's directors include Vidyut Dilip Shah, Susie Vidyut Shah, Purvesh Dilip Shah, Aditya Vidyut Shah, Radhika Vidyut Shah, and Nimesh Shashikant Shah. Specific roles and responsibilities of each director are not publicly detailed. The company's management is committed to maintaining high standards in pharmaceutical manufacturing and export operations.

V S International Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and market access in these regions, ensuring compliance with stringent quality and safety standards. This enables V S International to export its pharmaceutical formulations to a global clientele, meeting the diverse healthcare needs of patients worldwide.

V S International Private Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company has pursued WHO prequalification for its products, facilitating access to these regions and enhancing its global footprint. By obtaining WHO prequalification, V S International demonstrates its commitment to meeting international quality standards, thereby increasing the trust and acceptance of its products in these emerging markets.

V S International Private Limited has adopted a diversified geographic strategy, exporting its pharmaceutical formulations to multiple regions worldwide. This approach mitigates concentration risk and allows the company to tap into various markets with differing demands. The strategic direction focuses on expanding the company's global presence while maintaining high-quality standards in manufacturing and export operations.

V S International Private Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. pharmaceutical regulations. The company has obtained approvals for its Abbreviated New Drug Applications (ANDAs) and has filed Drug Master Files (DMFs) with the FDA. Inspection histories indicate that the facilities have met FDA standards, reflecting the company's commitment to quality and regulatory compliance in the U.S. market.

V S International Private Limited has achieved WHO prequalification for its products, demonstrating adherence to international quality standards. The company holds EU Good Manufacturing Practice (GMP) certificates, ensuring that its manufacturing processes meet the stringent requirements set by the European Medicines Agency (EMA). Additionally, V S International complies with the European Directorate for the Quality of Medicines & HealthCare (EDQM) standards, further affirming the quality and safety of its pharmaceutical formulations.

V S International Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has obtained approvals from state drug controllers for its manufacturing facilities and has received export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), authorizing the export of its pharmaceutical products. These regulatory approvals underscore the company's compliance with Indian pharmaceutical regulations and its commitment to quality in manufacturing and export operations.

As of March 28, 2026, there are no publicly available records indicating that V S International Private Limited has received Form 483 observations, warning letters, or import alerts from regulatory authorities such as the FDA. This absence suggests that the company maintains a strong compliance record and adheres to the regulatory standards set by health authorities.

V S International Private Limited operates in a competitive landscape, with several key players in the pharmaceutical export sector. While specific competitors are not identified in the available data, the company's focus on high-quality finished pharmaceutical formulations positions it favorably in the market. The company's adherence to international quality standards, such as WHO prequalification and EU GMP certifications, enhances its competitiveness and appeal to global clients seeking reliable pharmaceutical suppliers.

V S International Private Limited's key differentiators include its diversified product portfolio, encompassing antibiotics, antivirals, and nutritional supplements. The company's commitment to quality is evidenced by its WHO prequalification and EU GMP certifications. Additionally, V S International's strategic geographic diversification allows it to mitigate risks associated with market concentration and respond effectively to global pharmaceutical demands.

V S International Private Limited's current strategic direction focuses on exporting high-quality finished pharmaceutical formulations to a global market. The company's future outlook includes expanding its product portfolio, enhancing manufacturing capabilities, and strengthening its presence in emerging markets. By maintaining a strong commitment to quality and regulatory compliance, V S International aims to achieve sustainable growth and establish itself as a leading player in the global pharmaceutical export sector.

V S International Private Limited has demonstrated a consistent track record in pharmaceutical manufacturing and export, with a total export value of $7.3 million USD and 196 shipments across six products in five therapeutic categories. The company's portfolio concentration, with the top five products accounting for 98.9% of exports, indicates a focused approach to product offerings. The company's adherence to international quality standards and regulatory compliance further underscores its reliability as a pharmaceutical supplier.

Importers should verify the following certifications when considering V S International Private Limited as a supplier:

• FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. pharmaceutical regulations.

• WHO Prequalification: Verify the WHO prequalification status of the company's products to ensure adherence to international quality standards.

• EU GMP Certification: Check for EU Good Manufacturing Practice certifications to confirm compliance with European manufacturing standards.

• EDQM Status: Ensure the company's compliance with the European Directorate for the Quality of Medicines & HealthCare standards.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting the company directly.

When conducting due diligence on V S International Private Limited, consider the following steps:

• Verify Regulatory Approvals: Confirm the company's manufacturing licenses, export NOCs, and certifications from relevant regulatory authorities.

• Assess Financial Health: Review the company's financial statements to evaluate profitability, revenue growth, and overall financial stability.

• Evaluate Manufacturing Capabilities: Assess the company's manufacturing facilities for compliance with international quality standards and capacity to meet order volumes.

• Check Compliance Records: Investigate any past regulatory actions, such as warning letters or import alerts, to assess the company's compliance history.

• Review Product Portfolio: Examine the company's product offerings to ensure they align with your requirements and meet quality standards.

Red flags to watch for include unresolved regulatory issues, financial instability, and a lack of transparency in operations. Recommended pre-order checks involve obtaining samples for quality assessment, verifying shipping and delivery capabilities, and ensuring clear communication channels for order processing.